Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHMT2 | P34897 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20138228 | 0.83 | BRD4 (0.31) | — | |
| SCHEMBL20138099 | 0.82 | TSHR (0.32) | SHMT2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20138056 | 0.82 | TSHR (0.32) | SHMT2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20137971 | 0.81 | SMN1; SMN2 (0.36) | SHMT2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20138189 | 0.78 | SMN1; SMN2 (0.34) | SHMT2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20138207 | 0.76 | SSTR5 (0.36) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20138097 | 0.73 | GRM2 (0.32) | SHMT2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20138002 | 0.72 | SHMT2 (0.35) | SHMT2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18305039 | 0.72 | IDO1 (0.30) | — | |
| SCHEMBL20138021 | 0.72 | EIF2AK4 (0.36) | SHMT2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | UCB S.A. (BE) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | TNF, NFKBIA, TNFRSF1A | SHMT2 2782/4885NPC1 4103/4885RAB9A 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.